Spruce Biosciences (SPRB) Enterprise Value (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Enterprise Value of -$54.1 million for Q1 2026, down 111.13% year-over-year from $486.1 million in Q1 2025, and down 10.58% quarter-over-quarter from -$48.9 million in Q4 2025.
Spruce Biosciences (SPRB) Enterprise Value (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Enterprise Value for 8 consecutive years, with -$54.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 111.13% year-over-year to -$54.1 million; the TTM figure through Mar 2026 stood at -$54.1 million (down 111.13% YoY), while the FY2025 annual figure was -$48.9 million, down 26.2% from the prior year.
- Enterprise Value retreated to -$54.1 million in Q1 2026 per SPRB's latest filing, from -$48.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$10.7 million in Q3 2025 and bottomed at -$120.5 million in Q2 2023.
- Historically, Enterprise Value has averaged -$70.8 million across 5 years, with a median of -$79.1 million in 2022.
- Annual changes were most pronounced in 2025 — Enterprise Value surged 82.23% — and 2026, when it plunged 111.13%.
- Spruce Biosciences' Enterprise Value stood at -$79.1 million in 2022, then fell by 21.83% to -$96.3 million in 2023, then soared by 59.77% to -$38.8 million in 2024, then slipped by 26.2% to -$48.9 million in 2025, then retreated by 10.58% to -$54.1 million in 2026.
- Business Quant data shows SPRB's Enterprise Value at -$54.1 million in Q1 2026, -$48.9 million in Q4 2025, and -$10.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | -96.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -96.30 Mn |
| Mar 31, 2026 | -54.08 Mn |
| Dec 31, 2025 | -48.91 Mn |
| Sep 30, 2025 | -10.67 Mn |
| Jun 30, 2025 | -16.39 Mn |
| Mar 31, 2025 | -25.62 Mn |
| Dec 31, 2024 | -38.75 Mn |
| Sep 30, 2024 | -60.06 Mn |
| Jun 30, 2024 | -69.68 Mn |
| Mar 31, 2024 | -81.15 Mn |
| Dec 31, 2023 | -96.34 Mn |
| Sep 30, 2023 | -108.03 Mn |
| Jun 30, 2023 | -120.52 Mn |
| Mar 31, 2023 | -118.59 Mn |
| Dec 31, 2022 | -79.08 Mn |
| Sep 30, 2022 | -90.40 Mn |
| Jun 30, 2022 | -93.30 Mn |
| Mar 31, 2022 | -91.35 Mn |
| Dec 31, 2021 | -88.97 Mn |
| Sep 30, 2021 | -92.32 Mn |